Skip to Main Content
Contribute Try STAT+ Today

One Medical announced its plan on Monday to acquire Iora Health, expanding its primary care services for the Medicare population. The all-stock transaction, valued at $2.1 billion, would bring together two longtime players in the virtual care space and add to One Medical’s already-growing physical footprint by taking on Iora’s 47 in-person medical offices, now serving about 38,000 Medicare patients.

“Today it seems obvious and almost fashionable to say that technology-powered primary care is the key to improving our health care system,” said Rushika Fernandopulle, CEO of Iora Health, in a call with investors Monday. “But almost 20 years ago small predecessor practices that became One Medical and Iora Health simply decided to start over, to build our own technology, membership models, salaried provider practices, and to emphasize relationships and not transactions.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.